MX2008002101A - Fusiones de la proteina-1 quimiotactica de monocito. - Google Patents

Fusiones de la proteina-1 quimiotactica de monocito.

Info

Publication number
MX2008002101A
MX2008002101A MX2008002101A MX2008002101A MX2008002101A MX 2008002101 A MX2008002101 A MX 2008002101A MX 2008002101 A MX2008002101 A MX 2008002101A MX 2008002101 A MX2008002101 A MX 2008002101A MX 2008002101 A MX2008002101 A MX 2008002101A
Authority
MX
Mexico
Prior art keywords
mcp1
fusions
polypeptides
immunoglobulin
linker
Prior art date
Application number
MX2008002101A
Other languages
English (en)
Inventor
Chuan-Chu Chou
Loretta A Bober
Lee Sullivan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2008002101A publication Critical patent/MX2008002101A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Abstract

La presente invencion proporciona polipeptidos que incluyen MCP1 fusionada, opcionalmente, por medio de un enlazador, a una inmunoglobulina. Tambien se cubren metodos para usar los polipeptidos en el tratamiento de trastornos medicos.
MX2008002101A 2005-08-12 2006-08-10 Fusiones de la proteina-1 quimiotactica de monocito. MX2008002101A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70773105P 2005-08-12 2005-08-12
PCT/US2006/031155 WO2007021807A1 (en) 2005-08-12 2006-08-10 Mcp1 fusions

Publications (1)

Publication Number Publication Date
MX2008002101A true MX2008002101A (es) 2008-04-19

Family

ID=37421010

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008002101A MX2008002101A (es) 2005-08-12 2006-08-10 Fusiones de la proteina-1 quimiotactica de monocito.

Country Status (12)

Country Link
US (3) US7713521B2 (es)
EP (1) EP1926747A1 (es)
JP (2) JP2009504158A (es)
KR (1) KR20080045158A (es)
CN (1) CN101443357A (es)
AU (1) AU2006280004A1 (es)
CA (1) CA2618951A1 (es)
IL (1) IL189414A0 (es)
MX (1) MX2008002101A (es)
NO (1) NO20081294L (es)
WO (1) WO2007021807A1 (es)
ZA (1) ZA200801606B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007113285A2 (en) * 2006-03-31 2007-10-11 Biotherapix Molecular Medicines S.L.U. Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors
AU2007278054B2 (en) * 2006-07-24 2012-11-22 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising CCL2 and use of same for the treatment of inflammation
EP2074428B1 (en) * 2006-09-29 2015-07-01 Roche Diagnostics GmbH Assessing the risk of disease progression for a patient with rheumatoid arthritis
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US9249204B2 (en) 2011-06-01 2016-02-02 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
JP2014518632A (ja) * 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
UA124083C2 (uk) 2011-06-28 2021-07-21 ІНГІБРЕКС, Інк. Злитий серпіновий поліпептид і спосіб його застосування
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
EP2791338B1 (en) * 2011-12-15 2019-02-20 The Royal Institution for the Advancement of Learning / McGill University Soluble igf receptor fc fusion proteins and uses thereof
US10155811B2 (en) * 2013-11-20 2018-12-18 Regeneron Pharmaceuticals, Inc. APLNR modulators and uses thereof
EP3096776B1 (en) 2014-01-22 2020-12-02 Antagonis Biotherapeutics GmbH Novel glycosaminoglycan-antagonising fusion proteins and methods of using same
KR20240005109A (ko) * 2014-10-27 2024-01-11 인히브릭스, 인크. 세르핀 융합 폴리펩티드 및 이의 사용 방법
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3253797A4 (en) * 2015-02-03 2018-10-03 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
US11376266B2 (en) * 2016-01-06 2022-07-05 Keio University Antitumor agent
KR20170123849A (ko) * 2016-04-29 2017-11-09 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP6987424B2 (ja) 2016-05-11 2022-01-05 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを洗浄および／または消毒する方法
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
CN109071613A (zh) 2016-05-11 2018-12-21 通用电气医疗集团生物工艺研发股份公司 分离基质
CN105920579A (zh) * 2016-06-13 2016-09-07 浙江生创精准医疗科技有限公司 Gro单独或与其他细胞因子联合在治疗肝纤维化中的用途
CN105944082B (zh) * 2016-06-13 2017-08-25 浙江生创精准医疗科技有限公司 骨保护素单独或与其他细胞因子联合在治疗肝纤维化中的用途
CN105944085A (zh) * 2016-06-13 2016-09-21 浙江生创精准医疗科技有限公司 Il-6单独或与其他细胞因子联合在治疗肝纤维化中的用途
CN105920585B (zh) * 2016-06-13 2019-07-09 浙江生创精准医疗科技有限公司 Mcp-1单独或与其他细胞因子联合在治疗肝纤维化中的用途
CN105944086B (zh) * 2016-06-13 2017-08-25 浙江生创精准医疗科技有限公司 Il‑8单独或与其他细胞因子联合在治疗肝纤维化中的用途
KR102065150B1 (ko) 2018-04-27 2020-01-10 (주)케어젠 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
CN114796264A (zh) * 2021-01-27 2022-07-29 北京北工大科技园有限公司 金络合物在制备治疗新型冠状病毒肺炎的药物中的应用
US11464464B2 (en) * 2020-07-24 2022-10-11 International Business Machines Corporation Internal and external proximate scanning
CN115704010A (zh) * 2021-08-11 2023-02-17 南京北恒生物科技有限公司 工程化免疫细胞及其用途
CN115192584A (zh) * 2022-06-09 2022-10-18 南方科技大学 一种纳米药物及其制备方法和应用

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
IL92938A (en) 1989-01-01 1998-08-16 Us Commerce A polypeptide that has a mutagenic activity on monocytes and AND that encodes it
IL92937A0 (en) 1989-01-31 1990-09-17 Us Health Human derived monocyte attracting protein,pharmaceutical compositions comprising it and dna encoding it
US6869924B1 (en) 1989-01-31 2005-03-22 The United States Of America As Represented By The Department Of Health And Human Services Human derived monocyte attracting purified protein product useful in a method of treating infection and neoplasms in a human body, and the cloning of full length cDNA thereof
US5216131A (en) 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US6787645B1 (en) 1989-05-12 2004-09-07 Dana-Farber Cancer Institute, Inc. DNA encoding human JE cytokine
US5179078A (en) 1989-05-12 1993-01-12 Dana Farber Cancer Institute Method of suppressing tumor formation in vivo
US5212073A (en) 1989-05-12 1993-05-18 Genetics Institute, Inc. Process for producing human JE cytokine
US6767535B1 (en) 1989-05-12 2004-07-27 Dana-Farber Cancer Institute, Inc. Suppressing tumor formation using cells expressing JE/monocyte chemoattractant protein-1
EP0732402A3 (en) 1990-12-14 1997-05-21 Cell Genesys Inc Chimeric chains for transduction of receptor-linked signaling pathways
WO1992019737A1 (en) 1991-05-09 1992-11-12 Dainippon Pharmaceutical Co., Ltd. Process for producing a monocyte chemotactic factor polypeptide and a strain for the production thereof
US5846717A (en) 1996-01-24 1998-12-08 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5605671A (en) 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
AU5537994A (en) 1992-10-22 1994-05-09 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
JPH09504422A (ja) 1993-07-29 1997-05-06 ジ・アップジョン・カンパニー 抗ヘパラナーゼ化合物を同定し、単離するためのヘパラナーゼの使用
US5510264A (en) 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
US5739103A (en) 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
US5459128A (en) 1993-11-12 1995-10-17 Dana-Farber Cancer Institute Human monocyte chemoattractant protein-1 (MCP-1) derivatives
WO1995019167A1 (en) 1994-01-14 1995-07-20 Mallinckrodt Medical, Inc. Therapeutic treatment for inhibiting vascular restenosis
CN1144845A (zh) 1995-03-01 1997-03-12 中国人民解放军军事医学科学院生物工程研究所 新型人粒细胞巨噬细胞集落刺激因子的融合蛋白
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
PL318594A1 (en) 1995-06-07 1997-06-23 Icos Corp Chemokine and analogues thereof originating from macrophages
CA2152141A1 (en) 1995-06-19 1996-12-20 Ian-Clark Lewis Monocyte chemoattractant protein (mcp)-1 antagonists
US6403782B1 (en) 1995-06-22 2002-06-11 President And Fellows Of Harvard College Nucleic acid encoding eotaxin
US6706471B1 (en) 1996-01-24 2004-03-16 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6780982B2 (en) 1996-07-12 2004-08-24 Third Wave Technologies, Inc. Charge tags and the separation of nucleic acid molecules
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
EP0972029A1 (en) 1997-03-07 2000-01-19 Human Genome Sciences, Inc. Human secreted proteins
WO1998045435A2 (en) 1997-04-10 1998-10-15 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6569418B1 (en) 1997-12-11 2003-05-27 University Of Maryland Biotechnology Institute Immuno-modulating effects of chemokines in DNA vaccination
US6607879B1 (en) 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
US6485910B1 (en) 1998-02-09 2002-11-26 Incyte Genomics, Inc. Ras association domain containing protein
ES2205849T3 (es) 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
CA2333901A1 (en) 1998-08-03 2000-02-24 East Carolina University Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
WO2000021991A1 (en) 1998-10-15 2000-04-20 Genetics Institute, Inc. SECRETED EXPRESSED SEQUENCE TAGS (sESTs)
US20040248169A1 (en) 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
EP1141011A2 (en) 1999-01-12 2001-10-10 Neorx Corporation Compounds and methods to inhibit or augment an inflammatory response
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US20020009730A1 (en) 1999-11-17 2002-01-24 Alex Chenchik Human stress array
WO2001042792A2 (en) 1999-12-08 2001-06-14 Millennium Pharmaceuticals, Inc. Diagnosis of cervical cancer using marker proteins
WO2001046697A2 (en) 1999-12-21 2001-06-28 Millennium Predictive Medicine Identification, assessment, prevention, and therapy of breast cancer
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030078396A1 (en) 2000-03-01 2003-04-24 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
AU2001258836A1 (en) 2000-05-26 2001-12-03 Kensuke Egashira Preventives and remedies for pulmonary hypertension
AU2001286890A1 (en) 2000-08-28 2002-03-13 Genaissance Pharmaceuticals, Inc. Haplotypes of the scya2 gene
US20030175704A1 (en) 2000-10-04 2003-09-18 Lasek Amy K. W. Genes expressed in lung cancer
US20020137081A1 (en) 2001-01-08 2002-09-26 Olga Bandman Genes differentially expressed in vascular tissue activation
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US20030073144A1 (en) 2001-01-30 2003-04-17 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002066510A2 (en) 2001-02-20 2002-08-29 K.U. Leuven Research And Development Regakine-1
WO2002081745A2 (en) 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
AU2002305236A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
WO2002085308A2 (en) 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20030166903A1 (en) 2001-04-27 2003-09-04 Anna Astromoff Genes associated with vascular disease
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
US20040077835A1 (en) 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US20030099974A1 (en) 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
EP1478773B1 (en) 2001-10-30 2007-09-19 Ortho-Clinical Diagnostics, Inc. Methods for assessing acute myeloid leukemia
US7304040B2 (en) 2001-11-02 2007-12-04 Kensuke Egashira Suppression of post-transplant arteriosclerosis
US20030129214A1 (en) 2002-01-10 2003-07-10 University Of Washington Methods of enhancing the biocompatibility of an implantable medical device
EP1497423A4 (en) 2002-03-26 2006-05-24 Centocor Inc MUTANT MCP-1 PROTEINS, ANTIBODIES, COMPOSITIONS, PROCESSES AND USES
GB0207624D0 (en) 2002-04-02 2002-05-15 Cancer Res Ventures Ltd Chemokine and uses thereof
BR0309238A (pt) 2002-04-10 2005-02-15 Applied Research Systems Antagonistas de proteìnas mcp
EP1578918A2 (en) 2002-04-23 2005-09-28 Duke University Atherosclerotic phenotype determinative genes and methods for using the same
JP2003310272A (ja) 2002-04-26 2003-11-05 Toshio Tanaka 血管拡張薬応答遺伝子の発現量変化を指標にした血管拡張物質の探索方法
EP1511846A4 (en) 2002-05-31 2007-03-28 Scegen Pty Ltd SELF-COAGULATING OR SELF-GOGGING PROTEINS DERIVED FROM A MEMBRANE TRANSLOCATION SEQUENCE
RU2339647C2 (ru) 2002-08-19 2008-11-27 Астразенека Аб Антитела против моноцитарного хемоаттрактантного белка-1 (мср-1) и их применение
CN1435433A (zh) 2002-08-30 2003-08-13 龚小迪 长效广谱的趋化因子受体抑制物
AU2002951346A0 (en) 2002-09-05 2002-09-26 Garvan Institute Of Medical Research Diagnosis of ovarian cancer
JP2006517388A (ja) 2002-10-04 2006-07-27 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 新規ケモカイン様ポリペプチド
US7595430B2 (en) 2002-10-30 2009-09-29 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
AU2003284357A1 (en) 2002-11-01 2004-06-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040157253A1 (en) 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
US7749714B2 (en) 2003-03-12 2010-07-06 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating prostate cancer
WO2004092368A1 (ja) 2003-03-13 2004-10-28 Banyu Pharmaceutical Co., Ltd. 肥満又は痩せの検査方法
JP2004307427A (ja) 2003-04-10 2004-11-04 Kensuke Egashira 腎虚血再灌流傷害の治療・改善・予防剤
EP1473304A1 (de) 2003-05-02 2004-11-03 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Verfahren zur Herstellung eines N-terminal modifizierten chemotaktischen Faktors
EP1961416B1 (en) 2003-05-05 2013-01-23 Probiodrug AG Use of inhibitors of glutaminyl cyclase for treating psoriasis, rheumatoid arthritis or atherosclerosis.
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
US20050002897A1 (en) 2003-06-18 2005-01-06 Ulrich Haupts Biological entities and the pharmaceutical or diagnostic use thereof
JP4635255B2 (ja) * 2003-09-02 2011-02-23 独立行政法人産業技術総合研究所 抗体医薬
AR046594A1 (es) 2003-10-16 2005-12-14 Applied Research Systems Usos terapeuticos de variantes de quemoquina
CA2544924A1 (en) 2003-11-05 2005-05-19 Centocor, Inc. Methods and compositions for treating mcp-1 related pathologies

Also Published As

Publication number Publication date
IL189414A0 (en) 2008-06-05
EP1926747A1 (en) 2008-06-04
AU2006280004A1 (en) 2007-02-22
NO20081294L (no) 2008-05-09
ZA200801606B (en) 2010-07-28
KR20080045158A (ko) 2008-05-22
WO2007021807A1 (en) 2007-02-22
WO2007021807A8 (en) 2008-06-05
CA2618951A1 (en) 2007-02-22
JP2008239633A (ja) 2008-10-09
US20070036750A1 (en) 2007-02-15
JP2009504158A (ja) 2009-02-05
US7972591B2 (en) 2011-07-05
US7713521B2 (en) 2010-05-11
CN101443357A (zh) 2009-05-27
US20110206669A1 (en) 2011-08-25
US8282914B2 (en) 2012-10-09
US20100172904A1 (en) 2010-07-08

Similar Documents

Publication Publication Date Title
MX2008002101A (es) Fusiones de la proteina-1 quimiotactica de monocito.
CY1118343T1 (el) Αντισωματα συνδεσης twεακ
BE2021C505I2 (es)
MX2009009773A (es) Sintesis de gamma-carbolinas fusionadas con heterociclo substituido.
IL195338A0 (en) Optimized fc variants and methods for their generation
SI1629011T1 (sl) Humane molekule za vezavo anti hu cd
MY156315A (en) Anti-vegf antibodies
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
UA101487C2 (en) Humanized b-ly1 antibody formulation
MX2009007145A (es) Conjugados de polimero con factor viii y factor de von willebrand que tienen una ligadura liberable.
TW200740844A (en) Novel MAdCAM antibodies
WO2006036445A3 (en) Chimeric nk receptor and methods for treating cancer
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2006127757A3 (en) Interferon-igg fusion
MX2009007290A (es) Compuestos agonistas del receptor de la proteina 1 similar al glucagon.
SG162687A1 (en) Caustic stable chromatography ligands
ZA200705874B (en) Process for producing polypeptide mixtures using hydrogenolysis
TN2009000239A1 (en) 4-phenyl-pyrane-3,5-diones,4-phenyl-thiopyrane-3,5-diones and cyclohexanetriones as novel herbicides
WO2007027805A3 (en) Method for generating anti-variable region monoclonal antibodies
DK2007885T3 (da) Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
MX2009004167A (es) Anticuerpos que enlazan epitopos cxcr7.
TR201818614T4 (tr) Bir Kromatografi Kolonunun Rejenerasyonuna Yönelik Yöntem
CA2705357C (en) Formulations for taci-immunoglobulin fusion proteins
EA200601219A1 (ru) Новые конденсированные пирролокарбазолы
EA200702543A1 (ru) Циклопентадиенильно-флуоренильные лиганды с углеродными мостиками

Legal Events

Date Code Title Description
FG Grant or registration